Factors Associated With Persistent Efficacy of Abrocitinib Without Flare: A Multivariable Analysis of the JADE-REGIMEN Study

BACKGROUND • Atopic dermatitis (AD) is a chronic skin disease that presents with eczematous lesions and intense pruritus1,2 • Patients with moderate-to-severe AD have a chronic, relapsing course that warrants systemic maintenance therapy in order to control disease and reduce the number and severity of flares1 • An important consideration when using long-term therapy is to use the lowest possible drug dose to reduce the risk for adverse events1 • JADE REGIMEN (NCT03627767) evaluated the efficacy and safety of continuous abrocitinib, dose reduction, or withdrawal of abrocitinib after induction of response with once-daily oral abrocitinib 200 mg in patients with moderate-to-severe AD3 • Predicting risk for disease flare can inform selection of appropriate maintenance therapy for patients with moderate-to-severe AD who achieve skin clearance after 12 weeks of induction monotherapy with abrocitinib 200 mg OBJECTIVES • To evaluate patient factors associated with a higher probability of persistent clinical response with different abrocitinib doses, with no protocol-defined flare, during a 40-week maintenance period • To create a nomogram, based on the patient factors identified above, to predict the probability of flare for individual patients with AD.